Acute Kidney Injury in Critically Ill Patients with Cancer

Critical Care Clinics

Volumn 26, Issue 1, 2010, Pages 151-179

  Benoit, Dominique D ^a   Hoste, Eric A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acute kidney injury; Cancer; ICU; Renal replacement therapy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BETA LACTAM ANTIBIOTIC; BORTEZOMIB; CASPOFUNGIN; CISPLATIN; CONTRAST MEDIUM; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; MELPHALAN; METHOTREXATE; MITOMYCIN C; PAMIDRONIC ACID; THALIDOMIDE; VANCOMYCIN; VINCRISTINE; VORICONAZOLE; ZOLEDRONIC ACID;

ARTIFICIAL VENTILATION; CRITICAL ILLNESS; DISEASE CLASSIFICATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INCIDENCE; INTENSIVE CARE; INTENSIVE CARE UNIT; KIDNEY INJURY; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NEOPLASM; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REHYDRATION; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR LYSIS SYNDROME; URETER OBSTRUCTION;

CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS; KIDNEY FAILURE, ACUTE; NEOPLASMS; RENAL REPLACEMENT THERAPY;

EID: 70450201360     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2009.09.002     Document Type: Review

References (144)

1. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360 9340 (2002) 1131-1135
2. Benoit D.D., Depuydt P.O., and Decruyenaere J.M. Should we remain reluctant to admit critically ill cancer patients to the intensive care unit?. In: Vincent J.-L. (Ed). Yearbook of intensive care and emergency medicine (2009), Springer-Verlag, Berlin/Heidelberg/New York 845-855
3. Darmon M., Ciroldi M., Thiery G., et al. Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care 10 2 (2006) 211
4. Brunet F., Lanore J.J., Dhainaut J.F., et al. Is intensive care justified for patients with haematological malignancies?. Intensive Care Med 16 5 (1990) 291-297
5. Evison J., Rickenbacher P., Ritz R., et al. Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors. Swiss Med Wkly 131 47-48 (2001) 681-686
6. Lanore J.J., Brunet F., Pochard F., et al. Hemodialysis for acute renal failure in patients with hematologic malignancies. Crit Care Med 19 3 (1991) 346-351
7. Azoulay E., and Afessa B. The intensive care support of patients with malignancy: do everything that can be done. Intensive Care Med 32 1 (2006) 3-5
8. Pène F., and Soares M. Can we still refuse ICU admission of patients with hematological malignancies?. Intensive Care Med 34 5 (2008) 790-792
9. Silfvast T., Pettila V., Ihalainen A., et al. Multiple organ failure and outcome of critically ill patients with haematological malignancy. Acta Anaesthesiol Scand 47 3 (2003) 301-306
10. Kroschinsky F., Weise M., Illmer T., et al. Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies. Intensive Care Med 28 9 (2002) 1294-1300
11. Groeger J.S., and Aurora R.N. Intensive care, mechanical ventilation, dialysis, and cardiopulmonary resuscitation. Implications for the patient with cancer. Crit Care Clin 17 3 (2001) 791-803 x
12. Benoit D.D., Hoste E.A., Depuydt P.O., et al. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies. Nephrol Dial Transplant 20 3 (2005) 552-558
13. Berghmans T., Meert A.P., Markiewicz E., et al. Continuous venovenous haemofiltration in cancer patients with renal failure: a single-centre experience. Support Care Cancer 12 5 (2004) 306-311
14. Darmon M., Thiery G., Ciroldi M., et al. Should dialysis be offered to cancer patients with acute kidney injury?. Intensive Care Med 33 5 (2007) 765-772
15. Soares M., Salluh J.I., Carvalho M.S., et al. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol 24 24 (2006) 4003-4010
16. Azoulay E., Alberti C., Bornstain C., et al. Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit Care Med 29 3 (2001) 519-525
17. Azoulay E., Moreau D., Alberti C., et al. Predictors of short-term mortality in critically ill patients with solid malignancies. Intensive Care Med 26 12 (2000) 1817-1823
18. Azoulay E., Recher C., Alberti C., et al. Changing use of intensive care for hematological patients: the example of multiple myeloma. Intensive Care Med 25 12 (1999) 1395-1401
19. Azoulay E., Thiery G., Chevret S., et al. The prognosis of acute respiratory failure in critically ill cancer patients. Medicine (Baltimore) 83 6 (2004) 360-370
20. Benoit D.D., Depuydt P.O., Peleman R.A., et al. Documented and clinically suspected bacterial infection precipitating intensive care unit admission in patients with hematological malignancies: impact on outcome. Intensive Care Med 31 7 (2005) 934-942
21. Benoit D.D., Vandewoude K.H., Decruyenaere J.M., et al. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med 31 1 (2003) 104-112
22. Depuydt P.O., Benoit D.D., Vandewoude K.H., et al. Outcome in noninvasively and invasively ventilated hematologic patients with acute respiratory failure. Chest 126 4 (2004) 1299-1306
23. Lamia B., Hellot M.F., Girault C., et al. Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU. Intensive Care Med 32 10 (2006) 1560-1568
24. Larchè J., Azoulay E., Fieux F., et al. Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 29 10 (2003) 1688-1695
25. Maschmeyer G., Bertschat F.L., Moesta K.T., et al. Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period. Eur J Cancer 39 6 (2003) 783-792
26. Peigne V., Rusinova K., Karlin L., et al. Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Med 35 3 (2009) 512-518
27. Pène F., Percheron S., Lemiale V., et al. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med 36 3 (2008) 690-696
28. Soares M., Carvalho M.S., Salluh J.I., et al. Effect of age on survival of critically ill patients with cancer. Crit Care Med 34 3 (2006) 715-721
29. Soares M., Darmon M., Salluh J.I., et al. Prognosis of lung cancer patients with life-threatening complications. Chest 131 3 (2007) 840-846
30. Soares M., Salluh J.I., Spector N., et al. Characteristics and outcomes of cancer patients requiring mechanical ventilatory support for >24 hrs. Crit Care Med 33 3 (2005) 520-526
31. Soares M., Salluh J.I., Toscano L., et al. Outcomes and prognostic factors in patients with head and neck cancer and severe acute illnesses. Intensive Care Med 33 11 (2007) 2009-2013
32. Taccone F.S., Artigas A.A., Sprung C.L., et al. Characteristics and outcomes of cancer patients in European ICUs. Crit Care 13 1 (2009) R15
33. Lecuyer L., Chevret S., Guidet B., et al. Case volume and mortality in haematological patients with acute respiratory failure. Eur Respir J 32 3 (2008) 748-754
34. Soares M., Salluh J.I., Torres V.B., et al. Short- and long-term outcomes of critically ill patients with cancer and prolonged ICU length of stay. Chest 134 3 (2008) 520-526
35. Merz T.M., Schar P., Buhlmann M., et al. Resource use and outcome in critically ill patients with hematological malignancy: a retrospective cohort study. Crit Care 12 3 (2008) R75
36. Cornet A.D., Issa A.I., van de Loosdrecht A.A., et al. Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care. Eur J Haematol 74 6 (2005) 511-516
37. Vandijck D.M., Benoit D.D., Depuydt P.O., et al. Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Med 34 5 (2008) 847-855
38. Benoit D.D., Depuydt P.O., Vandewoude K.H., et al. Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit. Intensive Care Med 32 1 (2006) 93-99
39. Darmon M., Thiery G., Ciroldi M., et al. Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 33 11 (2005) 2488-2493
40. Bach P.B., Schrag D., Nierman D.M., et al. Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood 98 12 (2001) 3234-3240
41. Letourneau I., Dorval M., Belanger R., et al. Acute renal failure in bone marrow transplant patients admitted to the intensive care unit. Nephron 90 4 (2002) 408-412
42. Pène F., Aubron C., Azoulay E., et al. Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol 24 4 (2006) 643-649
43. Vieira Jr. J.M., Castro I., Curvello-Neto A., et al. Effect of acute kidney injury on weaning from mechanical ventilation in critically ill patients. Crit Care Med 35 1 (2007) 184-191
44. Parikh C.R., and Coca S.G. Acute renal failure in hematopoietic cell transplantation. Kidney Int 69 3 (2006) 430-435
45. Bellomo R., Ronco C., Kellum J.A., et al. Acute renal failure- definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 4 (2004) R204-R212
46. Hoste E.A., and Schurgers M. Epidemiology of acute kidney injury: how big is the problem?. Crit Care Med 36 4 Suppl (2008) S146-S151
47. Mehta R.L., Kellum J.A., Shah S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11 2 (2007) R31
48. Kellum J.A. Defining and classifying AKI: one set of criteria. Nephrol Dial Transplant 23 5 (2008) 1471-1472
49. Bagshaw S.M., George C., and Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care 11 3 (2007) R68
50. Bagshaw S.M., Laupland K.B., Doig C.J., et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 9 6 (2005) R700-R709
51. de Mendonça A., Vincent J.L., Suter P.M., et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 26 7 (2000) 915-921
52. Uchino S., Kellum J.A., Bellomo R., et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294 7 (2005) 813-818
53. Tanvetyanon T., and Leighton J.C. Life-sustaining treatments in patients who died of chronic congestive heart failure compared with metastatic cancer. Crit Care Med 31 1 (2003) 60-64
54. Chertow G.M., Christiansen C.L., Cleary P.D., et al. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 155 14 (1995) 1505-1511
55. Hoste E.A., Lameire N.H., Vanholder R.C., et al. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 14 4 (2003) 1022-1030
56. Soares M., Salluh J.I., Ferreira C.G., et al. Impact of two different comorbidity measures on the 6-month mortality of critically ill cancer patients. Intensive Care Med 31 3 (2005) 408-415
57. Massion P.B., Dive A.M., Doyen C., et al. Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med 30 10 (2002) 2260-2270
58. Rubenfeld G.D., and Crawford S.W. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med 125 8 (1996) 625-633
59. Drake M.T., Clarke B.L., and Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83 9 (2008) 1032-1045
60. Vandijck D.M., and Benoit D.D. Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies: reply to letter by Meyer et al. Intensive Care Med 34 10 (2008) 1930-1931
61. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 19 (2001) 1368-1377
62. Hilbert G., Gruson D., Vargas F., et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 344 7 (2001) 481-487
63. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 10 (2001) 699-709
64. Dhainaut J.F., Shorr A.F., Macias W.L., et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 33 2 (2005) 341-348
65. Shimamura K., Oka K., Nakazawa M., et al. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med 107 10 (1983) 543-547
66. Gupta A., Berg D.T., Gerlitz B., et al. Role of protein C in renal dysfunction after polymicrobial sepsis. J Am Soc Nephrol 18 3 (2007) 860-867
67. Sharfuddin A.A., Sandoval R.M., Berg D.T., et al. Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 20 3 (2009) 524-534
68. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 6 (2002) 730-751
69. Paul M., Benuri-Silbiger I., Soares-Weiser K., et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 328 7441 (2004) 668
70. Paul M., Soares-Weiser K., and Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 326 7399 (2003) 1111
71. Smyth A.R., and Tan K.H. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 3 (2006) CD002009
72. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66 1 (2009) 82-98
73. Hidayat L.K., Hsu D.I., Quist R., et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166 19 (2006) 2138-2144
74. Lodise T.P., Lomaestro B., Graves J., et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrobial Agents Chemother 52 4 (2008) 1330-1336
75. Eriksson U., Seifert B., and Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled. BMJ 322 7286 (2001) 579 [Clinical research ed.]
76. Blot S., and Vandewoude K. Management of invasive candidiasis in critically ill patients. Drugs 64 19 (2004) 2159-2175
77. McCullough P.A. Contrast-induced acute kidney injury. J Am Coll Cardiol 51 15 (2008) 1419-1428
78. Tumlin J., Stacul F., Adam A., et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 98 6A (2006) 14K-20K
79. McCarthy C.S., and Becker J.A. Multiple myeloma and contrast media. Radiology 183 2 (1992) 519-521
80. Merten G.J., Burgess W.P., Gray L.V., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291 19 (2004) 2328-2334
81. Hoste E.A.J., De Waele J.J., Gevaert S.A., et al. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant (2009) [Epub ahead of print]
82. Vaitkus P.T., and Brar C. N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses. Am Heart J 153 2 (2007) 275-280
83. Hoffmann U., Fischereder M., Kruger B., et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15 2 (2004) 407-410
84. Marenzi G., Lauri G., Campodonico J., et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 119 2 (2006) 155-162
85. Arany I., and Safirstein R.L. Cisplatin nephrotoxicity. Semin Nephrol 23 5 (2003) 460-464
86. Schuchter L.M., Hensley M.L., Meropol N.J., et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20 12 (2002) 2895-2903
87. Widemann B.C., and Adamson P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist 11 6 (2006) 694-703
88. Pauley J.L., Panetta J.C., Schmidt J., et al. Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol 54 2 (2004) 146-152
89. Buchen S., Ngampolo D., Melton R.G., et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 92 3 (2005) 480-487
90. Cairo M.S., and Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127 1 (2004) 3-11
91. Davidson M.B., Thakkar S., Hix J.K., et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116 8 (2004) 546-554
92. Darmon M., Roumier M., and Azoulay E. Acute tumor lysis syndrome: diagnosis and management. In: Vincent J.-L. (Ed). Yearbook of intensive care and emergency medicine (2009), Springer-Verlag, Berlin/Heidelberg/New York 819-827
93. Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol 22 1 (2009) 129-136
94. Sallah S., Wan J.Y., Nguyen N.P., et al. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 86 3 (2001) 828-833
95. Stein E., McMahon B., Kwaan H., et al. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 22 1 (2009) 153-163
96. Bell W.R., Starksen N.F., Tong S., et al. Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med 79 4 (1985) 423-430
97. Callander N., and Rapaport S.I. Trousseau's syndrome. West J Med 158 4 (1993) 364-371
98. Miyashita M., Onda M., Sasajima K., et al. Multiple organ failure without sepsis following surgical treatment of advanced gastric carcinoma. Jpn J Surg 18 6 (1988) 705-708
99. Sack Jr. G.H., Levin J., and Bell W.R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56 1 (1977) 1-37
100. Taccone F.S., Jeangette S.M., and Blecic S.A. First-ever stroke as initial presentation of systemic cancer. J Stroke Cerebrovasc Dis 17 4 (2008) 169-174
101. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110 6 (2007) 1723-1729
102. Voulgaris E., Pentheroudakis G., Vassou A., et al. Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature. Lung Cancer 64 2 (2009) 247-249
103. Langer F., Spath B., Haubold K., et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol 87 6 (2008) 451-457
104. Chalela J.A., Raps E.C., and Kasner S.E. Disseminated intravascular coagulation and stroke associated with cervical cancer. J Stroke Cerebrovasc Dis 8 5 (1999) 355-357
105. Smeglin A., Ansari M., Skali H., et al. Marantic endocarditis and disseminated intravascular coagulation with systemic emboli in presentation of pancreatic cancer. J Clin Oncol 26 8 (2008) 1383-1385
106. Lesesne J.B., Rothschild N., Erickson B., et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 7 6 (1989) 781-789
107. Francis K.K., Kalyanam N., Terrell D.R., et al. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases. Oncologist 12 1 (2007) 11-19
108. Levandovsky M., Harvey D., Lara P., et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol Oncol 1 (2008) 23
109. Miller D.P., Kaye J.A., Shea K., et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology 15 2 (2004) 208-215
110. Chang J.C., and Naqvi T. Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer. Oncologist 8 4 (2003) 375-380
111. Spoormans I., Altintas S., Van den Brande J., et al. Purpura in a patient with disseminated breast cancer: a rapidly progressive cancer-related thrombotic thrombocytopenic purpura. Ann Oncol 19 6 (2008) 1204-1207
112. Werner T.L., Agarwal N., Carney H.M., et al. Management of cancer-associated thrombotic microangiopathy: what is the right approach?. Am J Hematol 82 4 (2007) 295-298
113. Snyder Jr. H.W., Mittelman A., Oral A., et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 71 5 (1993) 1882-1892
114. Zupancic M., Shah P.C., and Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 8 7 (2007) 634-641
115. Cantrell Jr. J.E., Phillips T.M., and Schein P.S. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 3 5 (1985) 723-734
116. Muller S., Schutt P., Bojko P., et al. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol 84 2 (2005) 110-114
117. Roy V., Rizvi M.A., Vesely S.K., et al. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 27 6 (2001) 641-646
118. Ganatra A.M., and Loughlin K.R. The management of malignant ureteral obstruction treated with ureteral stents. J Urol 174 6 (2005) 2125-2128
119. Kouba E., Wallen E.M., and Pruthi R.S. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol 180 2 (2008) 444-450
120. Wong L.M., Cleeve L.K., Milner A.D., et al. Malignant ureteral obstruction: outcomes after intervention. Have things changed?. J Urol 178 1 (2007) 178-183 [discussion: 183]
121. Gertz M.A. Current therapy of myeloma induced renal failure. Leuk Lymphoma 49 5 (2008) 833-834
122. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78 1 (2003) 21-33
123. Eleutherakis-Papaiakovou V., Bamias A., Gika D., et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48 2 (2007) 337-341
124. Knudsen L.M., Hjorth M., and Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65 3 (2000) 175-181
125. Clark W.F., Stewart A.K., Rock G.A., et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 143 11 (2005) 777-784
126. Hutchison C.A., Bradwell A.R., Cook M., et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 4 4 (2009) 745-754
127. Huang Z.Q., and Sanders P.W. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 99 4 (1997) 732-736
128. Herrera G.A. Renal lesions associated with plasma cell dyscrasias: practical approach to diagnosis, new concepts, and challenges. Arch Pathol Lab Med 133 2 (2009) 249-267
129. Lameire N., Van Biesen W., and Vanholder R. Acute renal problems in the critically ill cancer patient. Curr Opin Crit Care 14 6 (2008) 635-646
130. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 18 (2004) 1860-1873
131. Tosi P., Zamagni E., Cellini C., et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 73 2 (2004) 98-103
132. Roussou M., Kastritis E., Migkou M., et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49 5 (2008) 890-895
133. Firkin F., Hill P.A., Dwyer K., et al. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis 44 3 (2004) 551-555
134. Lorenz E.C., Gertz M.A., Fervenza F.C., et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 23 6 (2008) 2052-2057
135. Thiery G., Azoulay E., Darmon M., et al. Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol 23 19 (2005) 4406-4413
136. Groeger J.S., Lemeshow S., Price K., et al. Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol 16 2 (1998) 761-770
137. Groeger J.S., White Jr. P., Nierman D.M., et al. Outcome for cancer patients requiring mechanical ventilation. J Clin Oncol 17 3 (1999) 991-997
138. Apatira L., Boyd E.A., Malvar G., et al. Hope, truth, and preparing for death: perspectives of surrogate decision makers. Ann Intern Med 149 12 (2008) 861-868
139. Wright A.A., Zhang B., Ray A., et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 300 14 (2008) 1665-1673
140. Steinhauser K.E., Christakis N.A., Clipp E.C., et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 284 19 (2000) 2476-2482
141. Emanuel L.L., Emanuel E.J., Stoeckle J.D., et al. Advance directives. Stability of patients' treatment choices. Arch Intern Med 154 2 (1994) 209-217
142. Emanuel E.J., Fairclough D.L., Wolfe P., et al. Talking with terminally ill patients and their caregivers about death, dying, and bereavement: is it stressful? Is it helpful?. Arch Intern Med 164 18 (2004) 1999-2004
143. Price K.J., and Kish S.K. End-of-life decisions in cancer care. Crit Care Clin 17 3 (2001) 805-811
144. Lecuyer L., Chevret S., Thiery G., et al. The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med 35 3 (2007) 808-814